Applied DNA Announces Closing of $15 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Announces Closing of $15 Million Registered Direct

Offering Priced At-the-Market Under Nasdaq Rules

N.Y. - January 13, 2021 - Applied DNA Sciences, Inc. (NASDAQ: APDN) (the "Company"), a leader in

Polymerase Chain Reaction (PCR)-based DNA manufacturing, announced today the closing of its previously announced registered

direct offering with a group of institutional investors of 1,810,000 shares of common stock at a price of $8.30 per share,

priced at-the-market under Nasdaq rules, resulting in total gross proceeds of approximately $15 million, before deducting the

placement agent's fees and other estimated offering expenses.

The Company currently intends to use the

net proceeds from the offering for general corporate purposes, including working capital, for research and development, and to

advance the adoption of its LinearDNA manufacturing platform.

Roth Capital Partners served as sole placement

agent for the transaction.

The offering was made pursuant to a shelf

registration statement on Form S-3 (File No. 333-238557) (including a prospectus) previously filed with the Securities and Exchange

Commission (the "SEC") on May 21, 2020, and declared effective by the SEC on June 1, 2020. A prospectus supplement and

the accompanying prospectus relating to and describing the terms of the offering was filed with the SEC and is available on the

SEC's website at www.sec.gov. Copies of the prospectus supplement and the accompanying prospectus relating to the offering may

also be obtained by contacting Roth Capital Partners, LLC, 888 San Clemente Drive, Newport Beach, California 92660, by calling

(800) 678-9147 or by e-mail at rothecm@roth.com.

This press release does not constitute

an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction

in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws

of any such state or jurisdiction.

About Applied DNA Sciences

Forward-Looking Statements

The statements made by Applied DNA in this

press release may be "forward-looking" in nature within the meaning of Section 27A of the Securities Act of 1933,

Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. Forward-looking statements

in this press release are subject to a number of risks and uncertainties, including, but not limited to market and other conditions

and the intended use of net proceeds from the offering. Forward-looking statements describe Applied DNA's future plans,

projections, strategies, and expectations, and are based on assumptions and involve a number of risks and uncertainties, many

of which are beyond the control of Applied DNA. Actual results could differ materially from those projected due to its history

of net losses, limited financial resources, limited market acceptance, the possibility that its assay kit could become obsolete

or have its utility diminished, the uncertainties inherent in research and development, future clinical data and analysis, including

whether any of Applied DNA's or its partner's diagnostic or therapeutic candidates will advance further in the preclinical

research or clinical trial process, including receiving clearance from the U.S. Food and Drug Administration (U.S. FDA) or equivalent

foreign regulatory agencies to conduct clinical trials and whether and when, if at all, they will receive final approval from

the U.S. FDA or equivalent foreign regulatory agencies, the unknown outcome of any applications or requests to U.S. FDA, equivalent

foreign regulatory agencies and/or the New York State Department of Health, the unknown limited duration of any Emergency Use

Authorization (EUA) approval from U.S. FDA, changes in guidances promulgated by the CDC, U.S. FDA and/or CMS relating to COVID-19

surveillance and diagnostic testing, disruptions in the supply of raw materials and supplies, and various other factors detailed

from time to time in Applied DNA's SEC reports and filings, including our Annual Report on Form 10-K filed on December 17,

2020, and other reports we file with the SEC, which are available at www.sec.gov. Applied DNA undertakes no obligation to

update publicly any forward-looking statements to reflect new information, events, or circumstances after the date hereof or to

reflect the occurrence of unanticipated events, unless otherwise required by law.

Investor contact: Sanjay

M. Hurry, Applied DNA Sciences, 917-733-5573, sanjay.hurry@adnas.com